<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03477604</url>
  </required_header>
  <id_info>
    <org_study_id>MMS-001</org_study_id>
    <nct_id>NCT03477604</nct_id>
    <nct_alias>NCT04025008</nct_alias>
  </id_info>
  <brief_title>A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)</brief_title>
  <official_title>A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Micro Medical Solution, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Micro Medical Solution, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized multicenter clinical trial consisting of two arms; one arm treated with PTA plus&#xD;
      the MicroStent® System and one arm treated with PTA alone. Purpose to evaluate the safety and&#xD;
      effectiveness of using the MicroStent® Peripheral Vascular Stent System, hereafter referred&#xD;
      to as the MicroStent® System, for the treatment of infrapopliteal lesions in subjects with&#xD;
      peripheral arterial disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patency of the target lesion</measure>
    <time_frame>up to 6 months after randomization</time_frame>
    <description>Primary patency defined as freedom from target lesion occlusion with no clinically driven target lesion reintervention, or major amputation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from perioperative death</measure>
    <time_frame>up to 30 days after randomization</time_frame>
    <description>Freedom from perioperative death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from major adverse limb event</measure>
    <time_frame>up to 6 months after randomization</time_frame>
    <description>Freedom from major adverse limb event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from major amputation above the ankle</measure>
    <time_frame>up to 6 months after randomization</time_frame>
    <description>Freedom from major amputation (above the ankle)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in size of ischemic leg/foot ulcers</measure>
    <time_frame>up to 6 months after randomization</time_frame>
    <description>Reduction in size of ischemic leg/foot ulcers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from major adverse limb event</measure>
    <time_frame>From date of randomization until the date of death from any cause assessed up to 36 months</time_frame>
    <description>Freedom from major adverse limb event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of serious adverse events and device and procedure related adverse events</measure>
    <time_frame>From date of randomization until the date of death from any cause assessed up to 36 months</time_frame>
    <description>Frequency and severity of serious adverse events and device and procedure-related adverse events at any time during the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">177</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>MicroStent and Standard PTA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implant of the MicroStent peripheral vascular stent system for treatment of arterial lesions below the knee.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard PTA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MicroStent and Standard PTA</intervention_name>
    <description>Self-expanding stent and standard PTA balloon</description>
    <arm_group_label>MicroStent and Standard PTA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard PTA</intervention_name>
    <description>Standard PTA balloon</description>
    <arm_group_label>Standard PTA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
          1. Subject is a male or a non-pregnant female adult between the age of 21 and 90 years&#xD;
             old.&#xD;
&#xD;
          2. Subject has documented clinical evidence of critical limb ischemia (CLI) in the target&#xD;
             limb prior to the index procedure, with a Rutherford Classification score of 4-5.&#xD;
&#xD;
          3. The subject, or subject's designated legal representative, has been informed of the&#xD;
             nature of the study and is willing to provide written informed consent.&#xD;
&#xD;
          4. Subject is willing to comply with all required follow-up visits.&#xD;
&#xD;
          5. Subject life expectancy is ≥1 year per the Principal Investigator.&#xD;
&#xD;
             Angiographic Inclusion Criteria&#xD;
&#xD;
          6. Target vessel reconstitutes at or above the ankle with inline flow to at least one&#xD;
             patent (&lt;50% stenosis) inframalleolar outflow vessel.&#xD;
&#xD;
          7. Subject has a lesion, with ≥ 70% stenosis and ≤ 12.0 cm in length located at or distal&#xD;
             to the tibial-peroneal trunk and above the tibiotalar joint; including the anterior&#xD;
             tibial, posterior tibial or peroneal arteries.&#xD;
&#xD;
          8. Target lesion has a reference vessel diameter of 2.5 - 4.5 mm&#xD;
&#xD;
          9. The target lesion is able to be crossed with a guidewire to facilitate treatment with&#xD;
             the randomized device.&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          1. Subject had a prior or has a planned index limb amputation above the ankle.&#xD;
&#xD;
          2. Subject has a wound/ulcer on the forefoot with a surface area &gt;4cm² or osteomyelitis&#xD;
             involving the calcaneus bone.&#xD;
&#xD;
          3. Subject is pregnant, plans to become pregnant, or is nursing.&#xD;
&#xD;
          4. Subject has clinical conditions that severely inhibit X-ray or duplex ultrasound&#xD;
             visualization (e.g. body habitus).&#xD;
&#xD;
          5. Subject has a history of hypercoagulation/clotting disorders or acute thrombosis.&#xD;
&#xD;
          6. Subject has allergy to iodinated contrast media that cannot be adequately managed with&#xD;
             medication.&#xD;
&#xD;
          7. Subject is in acute renal failure.&#xD;
&#xD;
          8. Subject has an active systemic infection.&#xD;
&#xD;
          9. Subject is participating in another research study involving an investigational&#xD;
             device, biologic, or drug that has not completed the primary endpoint at the time of&#xD;
             randomization/enrollment.&#xD;
&#xD;
         10. Subject has other comorbidities that - in the opinion of the investigator - preclude&#xD;
             them from receiving study treatment and/or from completing the required study&#xD;
             follow-up assessments.&#xD;
&#xD;
         11. Subject presents with acute limb ischemia or acute thrombosis of the target limb.&#xD;
&#xD;
         12. Subject has experienced myocardial infarction, thrombolysis, or angina less than 30&#xD;
             days prior to the index procedure.&#xD;
&#xD;
         13. Subject had a stroke within 3 months of index procedure.&#xD;
&#xD;
             Angiographic exclusion criteria&#xD;
&#xD;
         14. Failure to successfully treat clinically significant inflow lesions in the ipsilateral&#xD;
             iliac, femoral, or popliteal arteries. Successful treatment is defined as obtaining&#xD;
             ≤30% residual stenosis with no major procedural complications (e.g embolism).&#xD;
&#xD;
         15. Failure to successfully treat significant non-target infra-popliteal lesions.&#xD;
             Successful treatment is defined as obtaining ≤30% residual stenosis with no major&#xD;
             procedural complications (e.g. embolism).&#xD;
&#xD;
         16. Target lesion is within a previously placed stent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kate Mandall</last_name>
    <phone>949-292-5466</phone>
    <email>kmandall@micromedicalsolutions.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiovascular Associates of the Southeast</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Stover</last_name>
      <email>tstover@cvapc.com</email>
    </contact>
    <investigator>
      <last_name>Jan Skowronski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Modern Vascular</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denisse Martinez Gaspar</last_name>
      <email>dmartinez@modernvascular.com</email>
    </contact>
    <investigator>
      <last_name>Scott Brannan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Regional VA Medical Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Palm Vascular</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Gimeno</last_name>
      <email>jennifer@palmvascular.com</email>
    </contact>
    <investigator>
      <last_name>Robert Beasley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Coast Cardiovascular Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Hudson</last_name>
      <phone>904-493-3333</phone>
      <phone_ext>1049</phone_ext>
      <email>mhudson@firstcoastcardio.com</email>
    </contact>
    <investigator>
      <last_name>Vaquar Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FHV Health</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shayna Rabess</last_name>
      <email>shayna.rabess@fhvhealth.com</email>
    </contact>
    <investigator>
      <last_name>David Lew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advent Health Sebring</name>
      <address>
        <city>Sebring</city>
        <state>Florida</state>
        <zip>33872</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Leicht</last_name>
      <email>James.Leicht@AdventHealth.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Shimshak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush Universtiy Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Villaneuva</last_name>
      <phone>312-563-7305</phone>
      <email>Karl_Villanueva@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Kumar Madassery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evansville Surgical Associates</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Midwest Cardiovascular Research Foundation</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Vascular Institute of the Midwest</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Jarrett</last_name>
      <phone>563-324-3818</phone>
      <email>lynn.jarrett@vimidwest.com</email>
    </contact>
    <investigator>
      <last_name>Eric Dippel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna Benoit</last_name>
      <email>Deanna.Benoit@cardio.com</email>
    </contact>
    <investigator>
      <last_name>Craig Walker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland - Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Hawkins</last_name>
      <email>skiddoo@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Khanjan Nagarsheth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Cardiac and Vascular Amputation Prevention Centers</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Finton</last_name>
      <email>sfinton@acvcenters.com</email>
    </contact>
    <investigator>
      <last_name>Fadi Saab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastlake Cardiovascular</name>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew McElvarr</last_name>
      <email>mcelvarra@deborah.org</email>
    </contact>
    <investigator>
      <last_name>Rich Kovach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Jersey Vascular Center</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>NC Heart and Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio Health Riverside Methodist</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Belcher</last_name>
      <email>christina.belcher@ohiohealth.com</email>
    </contact>
    <investigator>
      <last_name>John Phillips, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lina Felix</last_name>
      <email>lfelix@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Peter Soukas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of East Texas</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZH/WAVE Vascular Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Kastern, MD</last_name>
      <email>bkastern@azhcenters.com</email>
    </contact>
    <investigator>
      <last_name>Awais Siddique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2018</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Below the knee</keyword>
  <keyword>Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

